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Background. Trastuzumab is successfully used for the treatment of HER2-positive breast
cancer. Because of its association with cardiotoxicity, LVEF is monitored by MUGA, though
this is a relatively late measure of cardiac function. Diastolic dysfunction (DD) is believed to be
an early predictor of cardiac impairment. We evaluate the merit of MUGA-derived diastolic
function parameters in the early detection of trastuzumab-induced cardiotoxicity (TIC).
Methods and Results. 77 trastuzumab-treated patients with normal baseline systolic and
diastolic function were retrospectively selected (n 5 77). All serial MUGA examinations were
re-analyzed for systolic and diastolic function parameters. 36 patients (47%) developed SD and
45 patients (58%) DD during treatment. Both systolic and diastolic parameters significantly
decreased. Of the patients with SD, 24 (67%) also developed DD. DD developed prior to systolic
impairment in 54% of cases, in 42% vice versa, while time to occurrence did not differ sig-
nificantly (P 5 .52). This also applied to the subgroup of advanced stage breast cancer patients
(P 5 .1).
Conclusions. Trastzumab-induced SD and DD can be detected by MUGA. An impairment
of MUGA-derived diastolic parameters does not occur prior to SD and therefore cannot be used
as earlier predictors of TIC. (J Nucl Cardiol 2016;23:824–32.)
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Abbreviations
SD Systolic dysfunction
DD Diastolic dysfunction
AIC Anthracycline-induced cardiotoxicity
TIC Trastuzumab-induced cardiotoxicity
LVEF Left ventricle ejection fraction
MUGA Multigated radionuclide angiography
PFR Peak filling rate
TPFR Time to peak filling rate
EDV End-diastolic volume
HER2 Human epidermal growth factor recep-
tor 2
INTRODUCTION
Trastuzumab is a recombinant humanized mono-
clonal antibody successfully used for the treatment of
human epidermal growth factor receptor2(HER2)-posi-
tive breast cancer. It prolongs the survival in metastatic
disease and, when combined with adjuvant chemother-
apy, also improves outcome in early stage breast
cancer.1 However, its use is associated with an increased
risk of cardiotoxicity, which frequently leads to tempo-
rary or definite discontinuation of trastuzumab therapy.
The overall incidence of trastuzumab-induced car-
diotoxicity (TIC) varies according to the definition used,
but ranges from 2% to 7% for trastuzumab monother-
apy, 2% to 13% for trastuzumab combined with
paclitaxel, and can be as high as 27% when used in
combination with anthracyclines.2 TIC is often transient
after discontinuation of trastuzumab, but may be irre-
versible if detected in a late stage.3,4 Cardiotoxicity may
be symptomatic with signs and symptoms of congestive
heart failure, but in the vast majority, it is asymptomatic.
If treatment with trastuzumab is continued despite a
decrease in cardiac function, severe and even irre-
versible loss of cardiac function may occur. Thus, close
cardiac monitoring in patients undergoing trastuzumab
therapy is of paramount importance.
Evaluation of the left ventricular systolic function
through measurement of the left ventricular ejection
fraction (LVEF), using multigated radionuclide angiog-
raphy (MUGA) or echocardiography, is the accepted
method in assessing cardiac function during trastuzumab
treatment. However, deterioration of LVEF only
becomes apparent if the myocardium has lost its
considerable functional reserve, and therefore is a
relatively late expression of left ventricular
dysfunction.5 The detection of changes in cardiac
parameters preceding decrease in LVEF allows the
identification of patients who might benefit from early
cardioprotective measures. Consequently, the likelihood
of discontinuation of effective systemic treatment,
potentially compromising the patients’ long-term out-
come, might be markedly reduced.
It has been shown that diastolic impairment of the
left ventricle occurs before deterioration in LVEF in
anthracycline-induced cardiotoxicity (AIC).6,7 For TIC,
Lange et al and Dores et al echocardiographically
studied diastolic dysfunction (DD) in relatively small
groups, but their results contradict.8,9 Cochet et al
evaluated MUGA-derived diastolic parameters and
found no significant impairment of diastolic function
during trastuzumab therapy, but they included only early
stage breast cancer patients, used a short follow-up
period of 1 year and did not study the time interval of
the first impairment of diastolic function.5
MUGA remains a reference technique for the eval-
uation of LVEF because of its standardized and
reproducible outcome. Apart from routine use for LVEF
determination, a MUGA study can provide diastolic
parameters. Peak filling rate (PFR) and time to peak filling
rate (TPFR) derived from the LV time-activity curve are
the commonly used diastolic parameters. A decrease and/
or delay in these parameters are typical disturbances of a
normal filling pattern. The lower limit of PFR is 2.50 end-
diastolic volumes per second (EDV/s). The TPFR is
expected to be less than 180 ms in a normal subject.10,11
Studies have demonstrated that diagnosing diastolic
abnormalities by a low PFR on MUGA correlates well
with changes seen on Doppler echocardiography.12
We hypothesized that a change in diastolic function
parameters measured by MUGA precedes deterioration
in LVEF. Therefore, we evaluated MUGA-derived
diastolic and systolic function parameters in breast
cancer patients treated with trastuzumab, in order to
determine whether diastolic function parameters can be
used as early detectors of TIC.
METHODS
Patient Population
HER2-positive female breast cancer patients, treated with
trastuzumab from 2003 to 2011 in the Radboud University
Medical Centre Nijmegen and with a MUGA examination
before trastuzumab, were retrospectively selected from regis-
tered data (n = 105). Both women with metastatic disease and
early stage breast cancer were included. Patients with a prior
history of severe cardiac events or an LVEF\ 50% were
excluded from trastuzumab therapy (n = 1). Patients with
abnormal baseline PFR or TPFR values (n = 27) were
See related editorial, pp. 833–836
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excluded from our primary analysis, but evaluated in a separate
subgroup analysis. The remaining study population consisted
of 77 subjects. Of these patients, the history of MUGA scans
and cardiac disease (until January 2015) was collected and
analyzed.
Treatment Regimens
After surgical staging, patients were selected for loco-
regional therapy and adjuvant treatment. In the non-metastatic
setting, patients received adjuvant chemotherapy with doxoru-
bicin, cyclophosphamide, a taxane, and trastuzumab. In the
metastatic setting, patients received several chemotherapeutic
regimens, consisting of anthracyclines, taxanes, bevacizumab,
capecitabine, CMF (cyclophosphamide, methotrexate, fluo-
rouracil), and FEC (fluorouracil, epirubucin,
cyclophosphamide) in divergent order, but all patients received
trastuzumab during a certain time span. Trastuzumab was
administered in a standard regimen: first dose at 8 mg/kg
followed by a 3-week schedule of 6 mg/kg diluted in 250 mL
of sodium chloride 0.9%. When SD was observed, trastuzumab
treatment was ceased or postponed until LVEF was recovered.
Multigated Radionuclide Angiography
All subjects underwent cardiac monitoring by serial
MUGA examinations at our institution. The baseline MUGA
was obtained before the start of treatment, with an every 3-
month assessment during therapy. The final examination was
acquired 1 year after completion of trastuzumab or earlier in
cases where discontinuation of therapy was indicated. MUGA
examinations were performed in supine position, with multiple
gated ECG-triggered sampling after injection of 740 MBq
(20 mCi) 99m-technetium radio-labeled red blood cells and
with acquisition from the left anterior oblique (LAO) view. 32
frames per cardiac cycle were used. The R-R interval and the
heart rate (beats/min) were recorded. Cardiac cycles with an R-
R interval outside 20% of the median were rejected. Acqui-
sition lasted till 600 accepted cycles were included.
MUGA recordings were re-analyzed for systolic and
diastolic function parameters. The reference parameter for
systolic function was LVEF, while reference parameters for
diastolic left ventricular function were PFR and TPFR. LVEF
was calculated from the time-activity curve; PFR and TPFR
were acquired from the first derivation of the time-activity
curve after cycle-dependent background correction, by a
clinically valid software program (Hermes Medical Solutions,
Stockholm). Cardiac systolic dysfunction (SD) was defined as
a LVEF\ 50% or a drop of 10 or more absolute points in
baseline LVEF.13 DD was defined as a PFR\ 2.5 EDV/s or a
TPFR[ 180 ms.5,11
Statistical Analysis
For all individuals, a time registration (in days) was made
from baseline MUGA up to the last examination after
treatment. Time intervals to first SD or DD were calculated.
If DD is an early detector of TIC, the time interval to first
impairment of diastolic parameters should be smaller than the
time interval to first impairment of systolic parameters. To test
these intervals, the following convention was used: if no
impairment of systolic parameters was seen, the time to SD
was set to the follow-up time. The same was done if no DD
was observed. A comparison of time intervals of the two
parameters was made using the Wilcoxon signed-rank test.
In-time differences of LVEF, PFR, and TPFR were tested
for significance with the paired t test and a Holms correction
for multiple testing was done.14 For the in-time assessment of
these parameters, the first six MUGA examinations were used.
The level of significance was set at 0.05. All calculations were
made with SPSS 20.0 for Windows.
RESULTS
Demographic and clinical characteristics of the
study population are displayed in Table 1. The number
of MUGA scans performed ranged from two to nineteen
per patient (median six, n = 46). The number varied
with disease stage and the patient’s tolerance of
trastuzumab (i.e., decrease of LVEF). In patients with
early stage breast cancer, trastuzumab was administered
for 1 year, corresponding with 17 cycles of 21 days.
Generally, patients with metastatic disease continued
trastuzumab therapy longer and underwent more MUGA
examinations. Those with poor tolerance of trastuzumab
and the possible need for therapy withdrawal were
monitored more frequently, with an increasing number
of scans and shorter time intervals. Necessity of addi-
tional scans was based on clinical grounds and at the
physician’s discretion. In the vast majority, MUGA
examinations were performed in a 3 monthly interval
during therapy. Follow-up of symptoms indicating
cardiac disease ranged from 33 to 117 months. One
patient developed clinical symptoms of cardiac failure
during therapy and follow-up. This patient showed both
DD and SD on MUGA, respectively, after 62 and
129 days. None of the other patients received additional
cardiac intervention during trastuzumab treatment or
follow-up.
Of the 77 subjects included in our study, SD at any
point in time during or after treatment was detected in 36
patients (47%, Table 2). Mean LVEF significantly
decreased in time (Figure 1), with a mean LVEF of
58.6% at MUGA 6. Of these 36, 11 (31%) still showed
SD at the last MUGA. 45 patients (58%) showed DD at
any time point, of which 39 patients showed a PFR of
\2.5 EDV/s and 26 showed a TPFR[ 180 ms. Nine-
teen patients had both abnormal PFR and TPFR. Both
parameters significantly decreased in time (Figure 1),
with a mean PFR of 2.8 EDV/s and a mean TPFR of
148 ms at MUGA 6. DD was present in 29 of 45 patients
(64%) at the last MUGA.
826 Reuvekamp et al Journal of Nuclear Cardiology
Does diastolic dysfunction precede systolic dysfunction July/August 2016
Of the 36 patients with LVEF values below normal,
24 (67%) showed also deterioration of PFR or TPFR. Of
these 24 patients, who were considered to have both SD
and DD, 13 patients (54%) showed DD prior to SD and
10 patients (42%) vice versa. Five of thirteen patients
recovered to baseline systolic function. In one patient, a
simultaneous decrease in systolic and diastolic function
was observed. Furthermore, in 21 of 77 patients (27%),
DD occurred without SD, while SD without DD
occurred in 12 patients (16%).
In the subgroup of 24 patients, the median time to
the first decrease was 122 days (range 36-581) for SD
and 121 days (range 9-672) for DD, which was not
significantly different (Wilcoxon signed-rank test,
P = .56). Comparison of time intervals between the
first moment of SD and DD in all patients, using the
Wilcoxon signed-rank test, did not show any significant
difference in both parameters (P = .10, Figure 2).
Subgroup Analyses
Next, we performed a subgroup analysis of patients
with early stage and advanced stage (i.e., metastatic)
breast cancer, since the latter group may have received
trastuzumab over a longer period of time, whereas
Table 1. Clinical characteristics of study population with normal (n = 77) and abnormal (n = 27)
diastolic function at baseline
Normal diastolic
function
Abnormal diastolic
function
Significance (P)N (%) Mean (SD) N (%) Mean (SD)
Clinical data
Age (years) 50.3 (10.4) 55.4 (7.8) \.05
BMI (kg/m2) 25.2 (4.4) 27.8 (5.2) \.05
Cardiovascular risk factors
Hypertension 11 (14) 10 (37)
Diabetes 3 (4) 1 (4)
Smoking 12 (16) 6 (22)
Use of AT blockers 3 (4) 5 (19)
Use of beta blockers 7 (9) 11 (41)
Cancer characteristics
Early stage breast cancer 64 (83) 16 (59)
Metastatic breast cancer 13 (17) 11 (41)
Location
Right breast 31 (40) 11 (41)
Left breast 44 (57) 13 (48)
Both sides 2 (3) 3 (11)
History of (neo)adjuvant anthracyclines 63 (82) 20 (74)
Left side radiation therapy 27 (35) 7 (26)
MUGA data (baseline)
General
Heart rate (beat/min) 76 (10.7) 76 (14) NS
R-R interval (ms) 801 (104) 820 (161) NS
Systolic function
LVEF (%) 63.6 (6.6) 59.9 (6.0) \.05
PER (EDV/s) 3.55 (0.59) 3.32 (0.52) NS
TPER (ms) 133 (20) 145 (25) \.05
Diastolic function
PFR (EDV/s) 3.42 (0.74) 2.74 (0.66) \.01
TPFR (ms) 137 (17) 190 (44) \.01
BMI, Body mass index; AT, angiotensin;MUGA, multigated radionuclide angiography; LVEF, left ventricular ejection fraction; PER,
peak ejection rate; EDV, end-diastolic volume; TPER, time to peak ejection rate; PFR, peak filling rate; TPFR, time to peak filling rate;
NS, not significant
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patients with early breast cancer were treated during a
fixed period of 12 months (Table 3). In both patient
groups, there was no significant difference detected.
To evaluate anthracycline influence, another sub-
group analysis was done in the small subgroup of
anthracycline naı¨ve patients (n = 14, Table 3). In this
group, we detected a significant difference in time to DD
compared to SD (P = .02).
Additionally, to assess radiation therapy influence, a
subgroup analysis was performed in left-sided radio-
therapy naı¨ve patients (n = 50). Although DD
developed before SD (median time 111 vs 133 days),
this was not significant according to the Wilcoxon
signed-rank test (P = .15, Table 3).
Subgroup Analysis of Patients with
Baseline DD
Twenty-seven patients were excluded from the
primary analysis due to DD at baseline. Of these, 10
patients had a PFR\ 2.5 EDV/s, twelve a
TPFR[ 180 ms, and five both. Patient characteristics
are displayed in Table 1. Besides a significant difference
in diastolic parameters, age, BMI, LVEF, and PER
differed from the initial patient group (Table 1).
Seventeen patients (63%) developed SD in a
median time of 116 days (range 28-1206). Mean LVEF,
however, did not significantly change in the course of
trastuzumab use (P = .08). Also, diastolic function
remained constant (PFR P = .14, TPFR P = .75).
DISCUSSION
Since subclinical signs of cardiac dysfunction are
supposed to predict the development of future heart
failure, many parameters of diastolic and systolic
function have been proposed to detect early cardiotox-
icity.15 However, conclusive evidence on the use of the
most optimal and meaningful combination of cardiac
function parameters is still lacking.
The present study retrospectively investigated whe-
ther impairment of systolic function is preceded by
MUGA-detectable DD in a group of 77 female breast
cancer patients undergoing trastuzumab therapy. The
results of this study showed a nearly even number of
patients with DD preceding SD (54%), as compared to
the number of patients with the opposite order (42%).
However, in 27% of patients, DD occurred without SD,
while in 16% SD was observed without deterioration of
diastolic function. Furthermore, in the relatively small
subgroup of advanced breast cancer patients, up to 85%
showed a decrease in diastolic function, in contrast with
54% SD. The time interval in which the patients
developed either one did not differ significantly. The
rates of DD and SD in the small subgroup of anthra-
cycline naı¨ve patients were 86% and 43%, respectively,
with significantly different time intervals. For radiation
therapy naı¨ve patients the differences were small (SD
42% and DD 56%). In general, both LVEF and diastolic
parameters significantly decreased due to trastuzumab
admission (Figure 1). Lastly, in the subgroup of patients
that suffered from baseline DD, 63% also developed SD,
but there was no significant decrease in systolic or
diastolic function.
Diastolic impairment is presumed to be an early
predictor of developing heart failure, thought to develop
before systolic impairment in AIC,5,6,16,17 while this is
not yet studied in TIC. In AIC, the endocardium is most
susceptible to the deleterious effects of anthracyclines,
resulting in interstitial fibrosis, while in the same stage
of disease the mid-myocardial fiber layers are not yet
affected.18 In TIC, the main pathophysiologic mecha-
nism is inhibition of HER2 in cardiomyocyte tissue. The
HER2 pathway is required for cell survival and contin-
uing function and seems to be stimulated in situations of
myocardial stress, such as anthracycline treatment.19
HER2 inhibition results in depletion of ATP and
subsequent dysfunction of contractility.20 For TIC, in
contrast to AIC, it has been shown that it is not dose
dependent, is often transient after drug discontinuation,
and can be safely re-administered after recovery of left
ventricular ejection fraction.19
The findings of the present study are supported by
the results of Lange et al8 and Dores et al9 and are also
in agreement with a previous report on short-term
anthracycline-based chemotherapy, showing simultane-
ous impairment of left ventricular systolic and diastolic
radionuclide parameters.21 Interestingly, although devel-
oped simultaneously, in our population we found that
31% and 64% of patients showed persistent SD and DD
Table 2. Frequencies of SD and DD in the total
population (n = 77)
N (%)
SD 36 (47)
DD 45 (58)
PFR\2.5 EDV/s 39 (87)
TPFR[180 ms 26 (58)
Abnormal PFR ? TPFR 19 (25)
DD ? SD 24 (31)
DD before SD 13 (54)
DD after or concurrent with SD 11 (46)
SD, Systolic dysfunction: LVEF\50% or a drop of 10 or more
absolute points in baseline LVEF; DD, diastolic dysfunction:
PFR\2.5 EDV/s or TPFR[180 ms; PFR peak filling rate;
TPFR, time to peak filling rate
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at their last MUGA scan. However, only one patient
developed symptomatic heart failure. This patient
showed persistent DD, but recovered systolic function
on the last MUGA.
Reduced diastolic (time to) peak filling rates are
thought to detect early chemotherapy-induced car-
diotoxicity with greater sensitivity, but to date the
additional value of these parameters in the prediction
of future heart failure, compared to serial MUGA-
based assessment of LVEF, has not been proven.22 Our
study evaluated the same parameters in a trastuzumab-
treated patient population and resulted in comparable
findings. It is the first study, however, that evaluates
the time to occurrence and includes patients with
metastatic disease in the evaluation.
In general, nearly all patients that do not have
metastases at diagnosis are treated with anthracyclines.
Consequently, it is expected that subgroups of anthracycline
naı¨ve and advanced stage patients are generally the same
and display a (nearly) identical cardiac dysfunction pattern.
Interestingly, we found a significant shorter time interval to
DD in the anthracycline naı¨ve subgroup, while subgroup
analyses of early vs advanced (i.e., with metastases) stage
did not show such a difference. However, the number of
patients in both subgroup analyses is small and therefore no
conclusions can be made based on this observation.
Figure 1. Serial results of left ventricle ejection fraction (LVEF, A), peak filling rate (PFR, B) and
time to peak filling rate (TPFR, C) at six time points, T1 depicting baseline scan and T2-T6
consecutive MUGA scans. Number of evaluated MUGA scans: T1 = 77, T2 = 74, T3 = 72,
T4 = 63, T5 = 46, and T6 = 46. In general, MUGA examinations are acquired every 3 months,
but can be made earlier at physicians’ discretion. Individual time points could therefore deviate
from population mean. All values are mean with 95% confidence interval.
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In general, reproducibility is very important for any
imaging method. In a recent review, the inter- and intra-
observer reproducibility of MUGA-derived LVEF
turned out to be near perfect.23 The reproducibility of
PFR and TPFR was already known to be excellent.24
Several other modalities in the early detection of
cardiotoxicity have been studied, although they mainly
focus on AIC. The two most promising cardiac serum
biomarkers are (high-sensitivity) Troponin I (TnI) and
N-terminal brain natriuretic peptide (NT-proBNP). A
study in 251 women receiving trastuzumab identified
TnI as a predictor of cardiotoxicity risk, but all patients
had a history of anthracycline treatment. It is therefore
not known whether increased TnI reflected AIC cat-
alyzed by trastuzumab, or true TIC.21
Other imaging modalities such as echocardio-
graphic strain (rate) imaging are thought to track early
changes in cardiac function by measuring the relative
deformation of myocardial segments and describing the
contraction/relaxation pattern of the heart.22,25 Although
only few studies assess the use of echocardiographic
strain (rate) imaging in TIC, these suggest that several
strain-derived parameters can be used as independent
early predictors for TIC.26-28
123I-meta-iodobenzylguanidine (123I-mIBG) is an
123I-labeled norepinephrine analog, used to noninva-
sively assess the sympathetic myocardial innervation.
Because 123I-mIBG is not metabolized, it deflects
neuronal integrity and eventually cardiac status.29 To
date, there is no experience in the use of 123I-mIBG for
the evaluation of TIC, except for a small study in 9
patients with a confirmed LVEF decrease, that suggests
that risk stratification and monitoring in this group is
possible.30
Cardiac magnetic resonance imaging (CMR) has
been studied in the assessment of TIC. Themain finding in
TIC is delayed enhancement of the LV lateral wall in the
mid-myocardial segment.27,31 In AIC, T1-weighted
hyperenhancement within three days of the first admin-
istration is associated with reduced LVEF on day 28 after
chemotherapy. Threshold values predicting LVEF
impairment are not yet known. Although CMR is expen-
sive, time-consuming, and less widely available, its great
accuracy and reproducibility will render CMR an impor-
tant cardiotoxicity imaging modality in the near future.20
Table 3. SD and DD in patient subgroups
Breast cancer stage Anthracycline use
Left-sided radiation
therapy
Early
(N 5 64)
Advanced
(N 5 13)
Naive
(N 5 14)
Treated
(N 5 63)
Naive
(N 5 50)
Treated
(N 5 27)
SD
N (%) 29 (45) 7 (54) 6 (43) 30 (48) 21 (42) 15 (56)
Median, days
(range)
129 (36–581) 138 (49–407) 150 (49–407) 122 (36–581) 133 (36–538) 129 (62–581)
DD
N (%) 34 (53) 11 (85) 12 (86) 33 (52) 28 (56) 17 (63)
Median, days
(range)
149 (17–672) 136 (9–573) 111 (9–573) 157 (18–672) 111 (18–575) 156 (9–663)
Wilcoxon signed-
rank test (SD vs
DD), P
0.26 0.12 0.02* 0.51 0.15 0.39
SD, Systolic dysfunction: LVEF\50% or a drop of 10 or more absolute points in baseline LVEF; DD, diastolic dysfunction:
PFR\2.5 EDV/s or TPFR[180 ms; PFR, peak filling rate; TPFR, time to peak filling rate
* P\0.05
Figure 2. Visualization of Wilcoxon signed-rank test showing
DD before SD in 34 cases and SD before DD in 22 cases. In
the other 21 cases, both events were simultaneous or did not
even occur. There was no significant difference in both groups
(P = .09).
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Study Limitations
In our study group, prior treatment with anthracy-
clines, radiotherapy, and/or concomitant heart failure
therapy (angiotensin blockers and beta blockers) could
have influenced the overall incidence of SD and DD.
This, however, adequately reflects the clinical situation
and gives the study a higher relevancy and applicability.
Above that, our aim was to detect a difference in the
time interval to SD or DD, not to estimate the overall
incidence of cardiac dysfunction. All the primary study
subjects had normal systolic and diastolic baseline
values and heart failure therapy was hardly used at
baseline (Table 1).
We did not observe a statistical significant differ-
ence in time to SD and DD between early and advanced
stage breast cancer patients or between patients that
were treated with or naı¨ve to left-sided radiation therapy.
This could be due to the small size of the subgroups.
However, we did observe a significant difference in
patients treated with or naı¨ve to anthracyclines, which is
expected to be even more significant if more patients
had been included. Therefore, we think this reflects a
relevant finding of our subgroup analysis.
In our institution, cardiotoxicity is defined as an
absolute drop of 10 percent points in LVEF or a
decrease below 50% in patients with baseline
LVEF[ 50%, thereby reducing the chance of false-
positive test results. However, more recent and com-
monly used guidelines define cardiotoxicity as a
reduction of LVEF of C5% to\55% with symptoms
of heart failure or an asymptomatic reduction of the
LVEF of C10% to \55%.32 Rates of SD may differ
according to the definition used, impeding inter-study
comparison. The definition used in our study may have
led to an underestimation of SD in our population,
however, without affecting study outcome.
Despite this, we found a high rate of SD in our study
population (47%), as well as an even higher rate of DD
(58%), which is discordant with reported literature
figures.2 There are several possible explanations for this.
First, this could be due to the fact that patients with
metastatic disease, with a generally longer duration of
treatment and thereby longer exposure to the deleterious
effects on cardiac function, were also included in our
study. Especially the rate of DD in the advanced stage
breast cancer patient group was markedly higher than in
the early stage breast cancer group (85% vs 53%).
However, rates of SD in both groups were only slightly
different: 45% in the group with early stage breast
cancer, and 54% in the group with metastatic disease.
Another explanation for the high incidence of SD could
be that due to the retrospective and clinical nature of the
study, patients with suboptimal cardiac function are still
included for trastuzumab treatment, while these patients
might have been excluded in a prospective trial. Con-
sequently, our group reflects a realistic group of breast
cancer survivors and is not biased toward optimal
cardiac function. Finally, in our institution, MUGA
examinations were done in a 3-month fashion, while in
other institutions this period might be longer and minor
changes in cardiac function are not detected.
CONCLUSION
The results of the present study show that both
trastzumab-induced SD and DD can be detected by
MUGA, but that there is no certain order of occurrence.
Therefore, MUGA-derived diastolic parameters seem
not suitable as earlier predictors of TIC. Newer promis-
ing imaging strategies in the early screening for
potential cardiotoxicity have been proposed. Further
clarification about the predictive value of these tech-
niques is much awaited.
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MUGA-derived DD seems not suitable for early
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